Syncom Formulations profit jumps 55% as revenue gains slow
Annual profit hit ₹76 crore on cost management, while fourth-quarter revenue contracted 10%.
What's new with Syncom Formulations (India) Ltd.
- Annual revenue grew 5% to ₹486.57 crore while net profit climbed 55.5%.
- Q4 revenue fell 10% to ₹134 crore even as quarterly profit rose 40%.
- Auditors issued an unmodified opinion with a restatement of prior EPS.
Why this matters for Syncom Formulations (India) Ltd.
The gap between falling sales and rising profit shows the company is protecting earnings by cutting costs. Top-line growth is stalling near single digits. The next test is whether the business can grow without relying on non-operational income.
What we're watching
- Whether the cost management trend continues if sales remain under pressure.
- Details on the technical EPS restatement.
- Sustainability of 'other income' as a driver for profit growth.
The full read
Syncom Formulations finished the year to March 2026 with a 55.5% profit gain, reaching ₹76.01 crore on a 5% revenue rise to ₹486.57 crore. The final quarter showed a sharp divide: revenue dropped 9.7% to ₹134 crore, yet profit climbed 40.4% to ₹24.57 crore. Management attributed the bottom-line shift to tighter cost management and non-operational income. The auditor provided an unmodified opinion, though a technical restatement of prior-period earnings per share was required. These results match expectations. The company is extracting more profit from a slowing top line. The drop in quarterly sales suggests the growth path is narrowing. The open question is how much further costs can be cut before the business hits a ceiling.